Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: Business Wire
NAARDEN, The Netherlands & MUNICH--(BUSINESS WIRE)-- Forbion today announces that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia. Under the terms of the agreement, Novo Nordisk will provide R&D funding and support for Staten to develop its lead asset STT-5058 for treatment of dyslipidaemia. Staten Biotechnology and its shareholders are entitled to receive signing and exercise fees, R&D funding, and milestone payments of up to 430 million euros. “We are very pleased that Staten, a company that we co-founded and built together with our sister-fund BGV, has been able to attract Novo Nordisk as a corporate partner in such a high-value transaction”, commented Sander van Deventer, Operating Partner at Forbion and Staten’s co-founder. “This partn
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $521.00 price target on the stock.MarketBeat
- argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.MarketBeat
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseGlobeNewswire
- Here's Why argenx SE (ARGX) Pulled Back 23% in Q4 [Yahoo! Finance]Yahoo! Finance
- argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.MarketBeat
ARGX
Earnings
- 2/29/24 - Miss
ARGX
Sec Filings
- 4/16/24 - Form 6-K
- 3/27/24 - Form 6-K
- 3/27/24 - Form 6-K
- ARGX's page on the SEC website